Preoperative transarterial chemoembolization and resection for hepatocellular carcinoma: A nationwide Taiwan database analysis of long-term outcome predictors

Journal of Surgical Oncology

Volumn 109, Issue 5, 2014, Pages 487-493

  Shi, Hon Yi ^a   Wang, Shen Nien ^b,c   Wang, Shih Chin ^a   Chuang, Shih Chang ^b,c   Chen, Chun Min ^d   Lee, King Teh ^a,b,c  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d University of Kang Ning   (Taiwan)

Author keywords

disease free survival; hepatocellular carcinoma; overall survival; transarterial chemoembolization

Indexed keywords

ADULT; ARTICLE; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HEALTH CARE PERSONNEL; HOSPITAL ADMISSION; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; LOGISTIC REGRESSION ANALYSIS; LONG TERM OUTCOME PREDICTOR; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT CODING; POPULATION; PREOPERATIVE CARE; PRIORITY JOURNAL; PROPENSITY SCORE; SURVIVAL PREDICTION;

DISEASE-FREE SURVIVAL; HEPATOCELLULAR CARCINOMA; OVERALL SURVIVAL; TRANSARTERIAL CHEMOEMBOLIZATION;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; CONFOUNDING FACTORS (EPIDEMIOLOGY); DATABASES, FACTUAL; DISEASE-FREE SURVIVAL; FEMALE; HEPATECTOMY; HEPATIC ARTERY; HEPATITIS B; HEPATITIS C; HOSPITALS; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TAIWAN; TREATMENT OUTCOME;

EID: 84897020286     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23521     Document Type: Article

References (36)

1. Huang JF, Wu SM, Wu TH, et al.: Liver resection for complicated hepatocellular carcinoma: Challenges but opportunity for long-term survivals. J Surg Oncol 2012; 106: 959-965.
2. Facciuto ME, Singh MK, Rochon C, et al.: Stereotactic body radiation therapy in hepatocellular carcinoma and cirrhosis: Evaluation of radiological and pathological response. J Surg Oncol 2012; 105: 692-698.
3. Shrager B, Jibara G, Schwartz M, et al.: Resection of hepatocellular carcinoma without cirrhosis. Ann Surg 2012; 255: 1135-1143.
4. Rahbari NN, Mehrabi A, Mollberg NM, et al.: Hepatocellular carcinoma: Current management and perspectives for the future. Ann Surg 2011; 253: 453-469.
5. Rahman A, Assifi MM, Pedroso FE, et al.: Is resection equivalent to transplantation for early cirrhotic patients with hepatocellular carcinoma? A meta-analysis. J Gastrointest Surg 2012; 16: 1897-1909.
6. Toro A, Pulvirenti E, Palermo F, et al.: Health-related quality of life in patients with hepatocellular carcinoma after hepatic resection, transcatheter arterial chemoembolization, radiofrequency ablation or no treatment. Surg Oncol 2012; 21: e23-e30.
7. Lee KT, Lu YW, Wang SN, et al.: The effect of preoperative transarterial chemoembolization of resectable hepatocellular carcinoma on clinical and economic outcomes. J Surg Oncol 2009; 99: 343-350.
8. Riaz A, Miller FH, Kulik LM, et al.: Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. JAMA 2010; 303: 1062-1069.
9. Joffe MM, Rosenbaum PR:, Invited commentary: Propensity scores. Am J Epidemiol 1999; 150: 327-333.
10. Rubin DB:, Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997; 127: 757-763.
11. Glasgow RE, Showstack JA, Katz PP, et al.: The relationship between hospital volume and outcomes of hepatic resection for hepatocellular carcinoma. Arch Surg 1999; 134: 30-35.
12. Yang T, Zhang J, Lu JH, et al.: Risk factors influencing postoperative outcomes of major hepatic resection of hepatocellular carcinoma for patients with underlying liver diseases. World J Surg 2011; 35: 2073-2082.
13. Fan ST, Mau Lo C, Poon RT, et al.: Continuous improvement of survival outcomes of resection of hepatocellular carcinoma: A 20-year experience. Ann Surg 2011; 253: 745-758.
14. Huang YS, Chiang JH, Wu JC, et al.: Risk of hepatic failure after transcatheter arterial chemoembolization for hepatocellular carcinoma: Predictive value of the monoethylglycinexylidide test. Am J Gastroenterol 2002; 97: 1223-1227.
15. Chan AO, Yuen MF, Hui CK, et al.: A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer 2002; 94: 1747-1752.
16. Pelletir G, Ducreux M, Gay F, et al.: Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: A multicenter randomized trial. Group CHC. J Hepatol 1998; 29: 129-134.
17. Wasif N, Bagaria SP, Ray P, et al.: Does metastasectomy improve survival in patients with Stage IV melanoma? A cancer registry analysis of outcomes. J Surg Oncol 2011; 104: 111-115.
18. Gonsalves WI, Wolpert J, Tashi T, et al.: Assessment of prognostic factors after primary tumor resection in metastatic colon cancer patients: A Veteran's Affairs Central Cancer Registry (VACCR) analysis, 1995-2008. J Surg Oncol 2012; 106: 486-490.
19. Cheng SH, Song HY:, Physician performance information and consumer choice: A survey of subjects with the freedom to choose between doctors. Qual Saf Health Care 2004; 13: 98-101.
20. Livingston EH, Cao J:, Procedure volume as a predictor of surgical outcomes. JAMA 2010; 304: 95-97.
21. Luo YQ, Wang Y, Chen H, et al.: Influence of preoperative transcatheter arterial chemoembolization on liver resection in patients with resectable hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2002; 1: 523-526.
22. Sasaki A, Iwashita Y, Shibata K, et al.: Preoperative transcatheter arterial chemoembolization reduces long-term survival rate after hepatic resection for resectable hepatocellular carcinoma. Eur J Surg Oncol 2006; 32: 773-779.
23. Zhang Z, Liu Q, He J, et al.: The effect of preoperative transcatheter hepatic arterial chemoembolization on disease-free survival after hepatectomy for hepatocellular carcinoma. Cancer 2000; 89: 2606-2612.
24. Majno PE, Adam R, Bismuth H, et al.: Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg 1997; 226: 688-701.
25. Sugo H, Futagawa S, Beppu T, et al.: Role of preoperative transcatheter arterial chemoembolization for resectable hepatocellular carcinoma: Relation between postoperative course and the pattern of tumor recurrence. World J Surg 2003; 27: 1295-1299.
26. Chen XP, Hu DY, Zhang ZW, et al.: Role of mesohepatectomy with or without transcatheter arterial chemoembolization for large centrally located hepatocellular carcinoma. Dig Surg 2007; 24: 208-213.
27. Kaibori M, Tanigawa N, Matsui Y, et al.: Influence of transcatheter arterial chemoembolization on the prognosis after hepatectomy for hepatocellular carcinoma in patients with severe liver dysfunction. Anticancer Res 2006; 26: 3685-3692.
28. Yamasaki S, Hasegawa H, Kinoshita H, et al.: A prospective randomized trial of the preventive effect of pre-operative transcatheter arterial embolization against recurrence of hepatocellular carcinoma. Jpn J Cancer Res 1996; 87: 206-211.
29. Harada T, Matsuo K, Inoue T, et al.: Is preoperative hepatic arterial chemoembolization safe and effective for hepatocellular carcinoma ? Ann Surg 1996; 224: 4-9.
30. Choi GH, Kim DH, Kang CM, et al.: Is preoperative transarterial chemoembolization needed for a resectable hepatocellular carcinoma ? World J Surg 2007; 31: 2370-2377.
31. Vogl TJ, Lammer J, Lencioni R, et al.: Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: Results from the PRECISION V randomized trial. Am J Roentgenol 2011; 197: W562-W570.
32. Xu LT, Zhou ZH, Lin JH, et al.: Clinical study of transarterial chemoembolization combined with 3-dimensional conformal radiotherapy for hepatocellular carcinoma. Eur J Surg Oncol 2011; 37: 245-251.
33. Meyer T, Kirkwood A, Roughton M, et al.: A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma. Br J Cancer 2013; 108: 1252-1259.
34. Uchida M, Kohno H, Kubota H, et al.: Role of preoperative transcatheter arterial oily chemoembolization for resectable hepatocellular carcinoma. World J Surg 1996; 20: 326-331.
35. Huang J, He X, Lin X, et al.: Effect of preoperative transcatheter arterial chemoembolization on tumor cell activity in hepatocellular carcinoma. Chin Med J 2000; 113: 446-448.
36. Kim YB, Park YN, Park C:, Increased proliferation activities of vascular endothelial cells and tumour cells in residual hepatocellular carcinoma following transcatheter arterial embolization. Histopathology 2001; 38: 160-166.